Cabaletta Bio, Inc.(CABA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CABA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Cabaletta Bio, Inc. (CABA), a Healthcare sector company. CABA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Cabaletta Bio, Inc. reports net income of $-51.0M, free cash flow of $-41.5M. Top institutional holders of CABA by reported 13-F value include JENNISON ASSOCIATES, T. Rowe Price Investment Management, Bain Capital Life Sciences Investors, based on the most recent SEC filings. CABA trades on the Nasdaq exchange and files with the SEC under CIK 1759138. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CABA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cabaletta Bio, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-51.0M
Free Cash Flow
Q2 2026
$-41.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-44.9% YoYOperating Income
-37.6% YoYEPS (Diluted)
+10.3% YoYTotal Assets
-10.8% YoYOp. Cash Flow
-48.6% YoYFree Cash Flow
-46.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-167.9M -44.9% | $-115.9M -71.2% | $-67.7M -27.7% | $-53.0M -14.4% | $-46.3M -38.8% | $-33.3M |
| Operating Income | $-172.2M -37.6% | $-125.1M -67.6% | $-74.7M -37.9% | $-54.1M -16.9% | $-46.3M -36.9% | $-33.8M |
| EPS (Diluted) | $-2.10 +10.3% | $-2.34 -41.8% | $-1.65 +8.8% | $-1.81 -0.6% | $-1.80 | — |
| Total Assets | $165.1M -10.8% | $185.0M -27.0% | $253.7M +116.9% | $117.0M -7.4% | $126.3M +10.1% | $114.7M |
| Operating Cash Flow | $-131.1M -48.6% | $-88.2M -64.8% | $-53.5M -15.5% | $-46.4M -36.0% | $-34.1M -27.4% | $-26.8M |
| Free Cash Flow | $-132.3M -46.3% | $-90.4M -66.7% | $-54.2M -11.1% | $-48.8M -38.4% | $-35.3M -28.7% | $-27.4M |
Get alerted when CABA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cabaletta Bio, Inc. including:
Top Institutional Holders of CABA
JENNISON ASSOCIATES LLC
$62.3M20,033,730 shT. Rowe Price Investment Management, Inc.
$58.7M18,869,907 shBain Capital Life Sciences Investors, LLC
$53.6M17,241,445 shBlackRock, Inc.
$33.4M10,754,701 shADAGE CAPITAL PARTNERS GP, L.L.C.
$28.5M9,174,758 shSTATE STREET CORP
$24.4M7,839,305 shVANGUARD CAPITAL MANAGEMENT LLC
$22.5M7,227,018 shCormorant Asset Management, LP
$15.6M5,000,000 shPRICE T ROWE ASSOCIATES INC /MD/
$13.7M4,418,674 shWoodline Partners LP
$13.1M4,200,142 sh
| Fund | Value | Shares |
|---|---|---|
| JENNISON ASSOCIATES LLC | $62.3M | 20,033,730 |
| T. Rowe Price Investment Management, Inc. | $58.7M | 18,869,907 |
| Bain Capital Life Sciences Investors, LLC | $53.6M | 17,241,445 |
| BlackRock, Inc. | $33.4M | 10,754,701 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $28.5M | 9,174,758 |
| STATE STREET CORP | $24.4M | 7,839,305 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.5M | 7,227,018 |
| Cormorant Asset Management, LP | $15.6M | 5,000,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $13.7M | 4,418,674 |
| Woodline Partners LP | $13.1M | 4,200,142 |
More Healthcare Companies
View all Healthcare →Put CABA on your watchlist
Track score changes the day Cabaletta Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CABA a good stock to buy?
13F Pro's AI-powered analysis of Cabaletta Bio, Inc. (CABA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CABA are available on the CABA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CABA is classified as a small company.
Which hedge funds own CABA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CABA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cabaletta Bio, Inc.'s investment landscape.